Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + olaparib versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer after prior next-generation hormonal therapy and chemotherapy
MOH_2019-03-28_006044Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab and olaparib in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Merck & Co. Started Mar 2019; status: active, not recruiting.
02
Drugs
pembrolizumabolaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on MOH_2019-03-28_006044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-03-28_006044.